NASDAQ:REPL

Replimune Group Stock Predictions

Healthcare > Biotechnology

Buy REPL

*Your capital is at risk

$9.68

-0.190 (-1.93%)

At Close: Jul 15, 2026

Currently predicting for Fri, 17 Jul 2026

REPL Live board

Community Bull/Bear

Target Next close

Join the REPL prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

REPL Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For REPL

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

REPL Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT REPLIMUNE GROUP INC.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
DHT $17.31	4.04%	Jul 13
SRPT $17.02	3.47%	Jun 29
NMRK $15.02	3.26%	Jun 24
JLL $299.78	9.38%	Jun 24
NESR $25.07	15.24%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by